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Abstract 
Background – Patients with Tetralogy of Fallot repair (rToF) who are approaching adulthood often 
exhibit pulmonary valve regurgitation, leading to right ventricle (RV) dilatation and dysfunction. The 
regurgitation can be corrected by pulmonary valve replacement (PVR) but the optimal surgical timing 
remains under debate, mainly due to the poorly understood nature of RV remodeling in rToF 
patients. The goal of the present study was to probe for pathologic molecular, cellular and tissue 
changes in the myocardium of rToF patients at the time of PVR. 
Methods and Results – We measured contractile function of permeabilized myocytes, collagen 
content of tissue samples, and the expression of mRNA and selected proteins in RV tissue samples 
from rToF patients undergoing PVR for severe pulmonary valve regurgitation. The data were 
compared with non-diseased RV tissue from unused donor hearts. Contractile performance and 
passive stiffness of the myofilaments in permeabilized myocytes were similar between rToF-PVR and 
RV donor samples, as was collagen content and crosslinking. There was enhanced mRNA expression 
in the rToF-PVR patients of genes associated with connective tissue diseases and tissue remodeling, 
including the small leucine-rich proteoglycans asporin, lumican and osteoglycin, although their 
protein levels were not significantly increased.  
Conclusions – RV myofilaments from rToF-PVR patients showed no functional impairment, but the 
changes in ECM gene expression may indicate the early stages of remodeling. Overall, our study 
found no evidence for major damage at the cellular and tissue levels in the RV of rToF patients who 
underwent PVR according to current clinical criteria.  
 
Keywords: 
Tetralogy of Fallot; pulmonary valve replacement; myofibril; extracellular matrix; small leucine rich 
proteoglycan 
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Non-standard Abbreviations and Acronyms 
CMR  cardiac magnetic resonance  
CPET  cardiopulmonary exercise test 
ECM  extracellular matrix 
EDVi  end-diastolic volume indexed for body surface area  
EF  ejection fraction 
ESVi  end-systolic volume indexed for body surface area   
GO  gene ontology 
GSEA  gene set enrichment analysis 
LV  left ventricle 
NYHA  New York Heart Association 
PVR  pulmonary valve replacement 
QC  quality control 
qPCR  quantitative polymerase chain reaction 
rToF  repair of Tetralogy of Fallot 
RV  right ventricle 
RVOT  RV outflow tract 
SLRP  small leucine rich proteoglycan 
SV  stroke volume 
TAPSE  tricuspid annular plane systolic excursion 
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Clinical Perspective 
What is new? 
• We found that the contractile function of the myofilaments in the right ventricular 
myocardium of repaired tetralogy of Fallot patients, taken at the time of pulmonary valve 
replacement (PVR), was similar to that in age-matched donor controls. 
• Similarly, the extracellular collagen matrix was similar to that in donor control tissue, but 
there were subtle changes in gene expression, particularly in small leucine-rich 
proteoglycans, although these changes were not reproduced at the protein level  
What are the clinical implications? 
• The optimal timing for PVR in repaired tetralogy of Fallot patients is controversial 
• It has been suggested that right ventricular dilation over the years preceding PVR could lead 
to pathological changes at the tissue and cellular levels that would limit long-term recovery 
post-PVR 
• Our finding of no evidence for myocyte or extracellular matrix remodeling suggests that 
patients are not exposed to detrimental or irreversible tissue remodeling with current PVR 
timing guidelines. 
• However, the subtle changes in gene expression may be indicate an impending program of 
myocardial remodeling 
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Introduction 
Tetralogy of Fallot (ToF) is one of the most common congenital heart diseases, accounting for almost 
10% of all cardiac malformations.1 Without surgical intervention only 10-15% of patients survive 
beyond the age of 20 years. The modern surgical approach for these patients is for a single-stage 
repair of ToF (rToF) performed during the first few months of life, which has led to excellent long-
term survival (>98% survival at 20 years after repair ).2 Nevertheless, residual hemodynamic lesions 
remain and need to be addressed to avoid long-term detrimental effects. The most common defect 
is pulmonary regurgitation, which is now recognized to have deleterious effect on global cardiac 
function, leading to progressive RV dilatation and dysfunction, tricuspid valve regurgitation, exercise 
intolerance, arrhythmias and sudden death.3-6 Pulmonary valve replacement (PVR) is therefore often 
advocated in the lifetime management of these patients. PVR has been shown in numerous studies 
to induce beneficial remodeling, not only of the RV but also the left ventricle (LV),7-9 coupled with 
improvement in patients’ symptoms and exercise capacity.7 However, the optimal timing for PVR is 
controversial. To date, all commercially-available pulmonary valves, whether surgically or 
percutaneously implanted, have a limited durability, hence exposing the patients to the need for 
multiple procedures during their lifetime. While the number of repeat procedures could be reduced 
by delaying PVR, any delay could also theoretically lead to irreversible changes in RV structure and 
function, potentially leading to poor long-term recovery in some patients after PVR. The timing of 
PVR is therefore critical. 
 In previous studies, we and others demonstrated a post-PVR positive remodeling, characterized 
by reduction of RV volumes, increase in LV filling and improvement of biventricular systolic function, 
across a range of ages but the greatest improvement of LV dynamics and exercise capacity was 
observed in younger patients (< 18 years). On pre-operative CMR and echocardiographic assessment, 
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the only difference we observed between younger and older patients was a higher pulmonary valve 
regurgitant fraction in the younger group, which we interpreted to be the result of a more compliant, 
less “diseased” right ventricle in younger patients.7 However, this suggestion highlighted a major 
deficiency in knowledge in this field: very little is known about the nature and extent of the 
pathological tissue changes that take place in the dilated RV as a result of severe pulmonary valve 
regurgitation, that is, by the time that PVR is performed, how severe is the cellular and tissue damage 
in the RV? 
 Chronic volume-overload of the left ventricle (for example, due to MI or aortic regurgitation) is 
associated with changes in the passive stiffness and contractile function of myocytes, and in the 
microarchitecture of the extracellular matrix (ECM), that may either contribute to, or compensate 
for, the mechanical dysfunction.10-12  However, it is not known if similar pathologies exist in the 
volume-overloaded RV myocardium of rToF patients at the time of PVR. Therefore, in this study we 
sought to assess the contractile properties and passive stiffness of the cardiac myofilaments, and the 
composition of the ECM, in these PVR patients in order to better understand the functional 
properties at the cellular level of the dilated right ventricle with significant pulmonary regurgitation. 
In the long term, an improved understanding of the nature and extent of the maladaptive RV 
remodeling may help to inform therapeutic strategies and aid clinical decisions regarding the time at 
which PVR should be performed in individual rToF patients. 
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Methods 
Data availability 
The data that support the findings of this study are available from the corresponding authors upon 
reasonable request. The microarray data are publicly accessible at the NCBI Gene Expression 
Omnibus (GEO) database (https://www.ncbi.nlm.nih.gov/geo/) under accession number 
GSE141955. 
 
Ethical approval 
 The project was approved by the UK National Research Ethics Committee (Rec #11/LO/1924) and 
by the local R&D committees of University College London Hospitals, Great Ormond Street Hospital, 
and Guy’s and St Thomas’s NHS Foundation Trust. Patients or their legal guardians (as appropriate) 
were approached at the time of pre-surgical assessment by one of the research fellows (HAJ and 
PKT). Signed, informed consent was obtained to allow the excised RV tissue to be retained for 
experimentation after the removal of residual excessive muscle bundles in the RV out-flow tract 
(RVOT). Consent was also obtained for the retrospective use of clinical data. To allow comparison 
with RV samples from non-diseased tissue, we also used frozen samples of RV tissue that had been 
obtained from 7 unused donor hearts; these were selected so that their gender and age profiles (4 
males, 3 females; patient age 28 ± 13 yr.) resembled those of the rToF-PVR patients. These samples 
were obtained from the Sydney Heart Bank, Australia, with full consent of the patients’ 
representatives and with ethics approval (Protocol no. 2012/2814) from the Human Research Ethics 
Committee of the University of Sydney.  
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Clinical Assessments  
 Eight patients (3 males, 5 females; patient age 24 ± 12 yr.), with previous ToF repair, underwent 
PVR for increasing RV volumes associated with symptoms of shortness of breath on exertion and/or 
palpitations (median NYHA class II) in agreement with current clinical indications. As part of their 
clinical pre-operative assessment, all patients underwent echocardiogram, cardiac magnetic 
resonance imaging (CMR), and cardio-pulmonary exercise testing (CPET), as described below and 
previously .13 
 
Echocardiography 
 Standard Doppler echocardiography was performed with a VIVID 7 machine (GE Medical 
Systems, Milwaukee, WI) equipped with a multi-frequency transducer (3.5 and 5 MHz) as previously 
described.7 From the apical view, tricuspid annular plane systolic excursion was obtained from M-
mode interrogation of the lateral aspect of the tricuspid valve. From the same apical views, tissue 
Doppler myocardial velocities were obtained at the RV and LV lateral annulus in order to assess 
longitudinal function. LV ejection fraction was calculated from the parasternal long axis view using 
Simpson’s formula. The degree of tricuspid valve regurgitation (TR) was assessed qualitatively using 
color Doppler from the apical four chamber view and from the short axis view; the regurgitation was 
graded as trivial, mild, moderate or severe according to the Doppler intensity. From the TR jet, the 
RV systolic pressure was obtained using the Bernoulli equation. Peak velocity gradient across the 
RVOT was calculated from the maximum velocity obtained from the continuous-wave Doppler 
signal.14 Pulmonary valve regurgitation was assessed by Color and Pulsed Doppler interrogation of 
the pulmonary valve (PHT less than 100 ms), and of the main pulmonary artery and branch pulmonary 
arteries (presence of reversal flow). 
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Cardiovascular Magnetic Resonance Imaging 
 Cardiovascular MR (CMR) was performed with a 1.5-T MR scanner (Avanto, Siemens Medical 
Systems) using techniques previously described.7 Assessment of LV and RV volumes was performed 
by manual segmentation of short-axis cine images at end-diastole and end-systole (Argus; Siemens 
Medical Systems). End-diastolic and end-systolic volumes were calculated by use of Simpson’s rule 
for each ventricle, and from these volumes, stroke volume (SV) and ejection fraction (EF) were 
calculated. Arterial blood flow was calculated from phase contrast images by use of a semiautomatic 
vessel edge-detection algorithm (Argus; Siemens Medical Systems) with operator correction. 
Pulmonary valve regurgitant fraction was calculated as percent backward flow over forward flow. All 
volume and flow measurements were indexed for body surface area. 
 
Cardiopulmonary Exercise Testing 
 Cardiopulmonary exercise testing was performed on an electronically-braked bicycle ergometer 
(Ergoline 900) with respiratory gas exchange analysis. We used a ramp protocol as previously 
described.7 Peak oxygen uptake (peak VO2), VO2 at the anaerobic threshold, and ventilatory response 
to carbon dioxide production (VE/VCO2 slope) were derived from respiratory gas analysis during 
maximal exercise testing; VE/VCO2 slope was measured as the slope for the whole exercise. 
 
Functional studies of human permeabilized cardiac myocytes 
We carried out functional studies of the myofilaments within human single permeabilized cardiac 
myocytes that had been prepared from rToF-PVR tissue and RV donor tissue. Myofilament contractile 
function was assessed from the following: passive myocyte stiffness (at <10 nmol/L Ca2+, which is 
below the threshold for Ca2+ activation of the myofilaments); force production of the myofilaments 
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when maximally activated with Ca2+ (30 µmol/L Ca2+); maximum rate of force redevelopment after a 
brief release/restretch of the myocyte during maximal Ca2+ activation (which gives information on 
the rate of actomyosin crossbridge cycling); Ca2+ sensitivity of myofilament force production, using a 
range of Ca2+ concentrations (0.1 - 30 µmol/L).  
 The permeabilized myocytes for these experiments were prepared at 4oC by a modification of 
the method used previously.15 A frozen piece of rToF-PVR tissue or donor RV tissue was homogenized 
for 7-10 s in a 1 ml ground-glass hand homogenizer containing skinning solution (= relaxing solution 
with 1% Triton-X100; ThermoFisher). Relaxing solution had the following composition (mmol/L): BES 
100, K propionate 55, Na2 phosphocreatine 10, Na2H2ATP 6.21 (for MgATP2- = 5), MgCl2 6.24 (for Mg2+ 
= 1), dithiothreitol 1, EGTA 10 (to maintain the free Ca2+ concentration at ~1 nM, pCa 9.0), and 
protease inhibitors leupeptin 0.001, E64 0.001, and AEBSF 0.25 (all from Sigma-Aldrich); pH 7.1 at 
4oC; ionic strength 0.20 mol/L. The homogenate in skinning solution was left on ice for 30 mins for 
permeabilization of the myocyte membranes, then was transferred into a Protein-LoBind Eppendorf 
tube (Fisher Scientific) and centrifuged (4000 rpm, 4.5 min). The myocyte pellet was washed three 
times in relaxing solution (4000 rpm, 4.5 min each time) to remove the Triton X-100. The final 
myocyte suspension in relaxing solution was then stored on ice. 
 The experimental protocol was modified slightly from that described previously.15 A 
permeabilized myocyte was selected and its ends were glued with UV-setting glue (OA63 adhesive 
and Opticure LED-200 UV light source, Norland)  between pins extending from a force transducer and 
a high-speed length controller (403A and 315C-I, Aurora Scientific Inc., Ontario, Canada). The mean 
sarcomere length (SL), measured using an Aurora 600A video analysis system in autocorrelation 
mode, was set to 2.0 μm. Myocytes were rejected if: the cell was visibly damaged; their end 
attachments were unstable; the resting sarcomere pattern was unclear or misaligned; the force 
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during Ca2+-activated contraction was unstable; the resting SL after a contraction was substantially 
different from that pre-contraction. These criteria, plus the fact that it was difficult to prepare more 
than a few myocytes from the small amounts of rToF-PVR tissue available, meant that it was 
impossible to obtain useful data from the same number of myocytes from each patient sample. The 
numbers of data-yielding myocytes from each donor or patient therefore ranged from one to six 
(details in Fig. 1 legend). 
 To measure its passive stiffness, the permeabilized myocyte was bathed in relaxing solution at 
15oC and given stretches of 1 s duration and various magnitudes to increase SL from 2.0 µm to within 
the range 2.1 – 2.3 µm.15 For the present study, we measured the force increment at the end of a  
stretch from SL 2.0 µm to 2.3 µm and used this increase in resting force as a measure of myocyte 
passive stiffness.  
 To examine the Ca2+-activated contractile performance of the permeabilized myocyte, we then 
perfused the myocyte with a series of CaEGTA-containing activating solutions of Ca2+ 0.1 – 30 µmol/L 
(pCa 7.0 – 4.5; pH 7.1; 15oC).15 Once force had developed to a steady level (Fig.1A), the myocyte was 
subjected to a release/restretch protocol to detach all the attached myosin crossbridges from actin. 
The subsequent recovery of force, as crossbridges re-attached to actin, was fitted with a single 
exponential fit and the rate constant of tension recovery (ktr) was used as a measure of crossbridge 
kinetics. Ca2+-activated force was measured as the total steady force in activating solution minus the 
preceding passive force (at SL 2.0 µm). The relationship between Ca2+-activated force and Ca2+ 
concentration of the activation solution was fitted with a sigmoidal curve (Hill equation), which was 
used to calculate the pCa required for 50% activation of force (pCa50). 
 The sensitivity of these techniques to detect functional changes in myocytes from diseased 
myocardium has been validated in our previous studies, where we found decreased maximum force 
13 
 
 
but increased ktr and Ca2+ sensitivity in myocytes from hypertrophic cardiomyopathy patients15 and 
increased Ca2+ sensitivity in myocytes from a dilated cardiomyopathy patient.16 
 
Histological quantification of collagen 
 Cryosections cut from frozen blocks of tissue were subjected to xylene clearance and sequential 
ethanol treatment. Slides were left in Milli-Q H2O for 5 min followed by a 30 second incubation in 
0.2% phosphomolybdic acid. Slides were rinsed in Milli-Q H2O and then left in 1% Sirius red solution 
(to stain for collagen) for 90 min. Slides were washed 2x2 min in acidified Milli-Q H2O (0.05% acetic 
acid), incubated for 15 min in Picric acid, rinsed 3 times in Milli-Q H2O, then dehydrated by sequential 
ethanol treatment: 25%, 50%, 75%, 96% (1 min each) 100%, (2x3 min) xylene, (2x5 min). Glass 
coverslips were mounted with DPX (Sigma Aldrich, UK) and allowed to dry overnight. Sections were 
viewed with a light microscope (Zeiss, Germany) without and with a polarization filter, to identify 
collagen organization. Images were captured and analyzed using Volocity software (Perkin Elmer). 
 
Microarray gene expression profiling  
 RNA extraction was performed on LN2 cooled and pulverized heart tissue samples using Direct-
zol™ RNA Miniprep plus kit according to the manufacturer’s instructions (Zymo Research Corp., CA, 
USA). RNA quality was assessed using the Agilent 2100 Bioanalyzer (Agilent Technologies LDA UK 
Limited, Stockport, United Kingdom) and quantified using the Nanodrop ND-1000 
Spectrophotometer (Thermo Fisher Scientific, Wilmington, USA). All seven rToF-PVR and six out of 
seven RV Donor samples passed quality control (QC) and were subsequently subjected to microarray 
analysis. The gene expression profiles were determined using the GeneChip Human Transcriptome 
2.0 Array (Affymetrix, ThermoFisher Scientific). Single Primer Isothermal Amplified (SPIA) cDNA was 
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generated using the Ovation Pico WTA System V2 kit (Nugen, AC Leek, The Netherlands) following 
the manufacturer’s instructions. In addition, the SPIA cDNA was subjected to a QC check to assess 
quality (Agilent 2100 Bioanalyzer) and quantity (Nanodrop ND-1000 Spectrophotometer) in 
preparation for the next stage. The SPIA cDNA was fragmented and biotin-labeled using the Encore 
Biotin Module (Nugen) according to the manufacturer’s instructions. The fragmented and biotin-
labeled cDNA was subjected to a further round of QC checks to assess fragmentation size (Agilent 
2100 Bioanalyzer). Hybridization cocktails were prepared from the fragmented labeled-cDNA 
according to Nugen’s recommendations and hybridized to the microarrays at 45°C for 18 hours. The 
arrays were washed and stained using the wash protocol FS450_0001 recommended for GeneChip 
Human Transcriptome 2.0 Arrays on the GeneChip Fluidics 450 station. The arrays were scanned 
using the GeneChip Scanner 3000 7G. CEL files were QC assessed in the Expression Console software 
package (Affymetrix, ThermoFisher Scientific) by using standard metrics and guidelines for the 
Affymetrix microarray system. Principle component analysis, hierarchical clustering and gene set 
enrichment analysis (GSEA) were performed in Qlucore Omics Explorer 3.0 (Qlucore, Lund, Sweden). 
Alignment and comparison to the Gene Ontology database of biological processes was performed in 
MetaCore™ (Thompson Reuters), and was used to identify processes and pathways represented by 
the differentially regulated genes. These microarray data have been submitted to NCBI GEO and are 
accessible through accession number GSE141955  
 
Quantitative PCR 
 2 μg RNA from the above extraction process was used to synthesize cDNA using an RT2 First-
strand kit (Qiagen). qPCR was carried out using the ΔCt method. 9 μl cDNA was added to 10 μl 2x Sybr 
green PCR master mix and 5 μmol of forward and reverse primers for the protein of interest (Table 
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1). Cycling parameters were 94°C for 15 seconds, followed by single-step annealing and extension at 
60°C for 1 min (35 cycles). Reactions were carried out in a Corbett RotorGene-3000. The cycle 
threshold (Ct) was determined automatically by the software and corresponds to a point during the 
linear phase of amplification. Gene expression of rToF-PVR samples was expressed as fold change 
compared to RV donor samples, by normalizing individual data points to the mean of RV donors 
(defined as the control group), which fixed the mean value for the RV donor group to 1. 
 
Extraction of ECM proteins  
 Tissue was washed in phosphate buffered saline (PBS) and then placed in 0.5 mol/L NaCl 
extraction buffer (1:10 weight:volume) and shaken (at low speed) for 1 hour at room temperature 
(RT). Decellularization was then performed in 0.1% SDS, with 25mM EDTA and 1:100 cocktail of 
protease inhibitors (1:10 weight:volume) and shaken for 18 hours at RT. Finally, samples were added 
to 4 mol/L guanidine-HCl (1:5 weight:volume) extraction buffer and shaken vigorously for 48 hours 
at RT to extract the strongly-bound ECM components. Guanidine extracts containing 25μg of protein 
were subjected to ethanol precipitation at -20⁰C overnight after adding 10x the volume of ethanol to 
the extract lysate. Samples were centrifuged at 14,000g for 45 minutes at 4⁰C. The supernatants were 
removed and the protein-containing pellets were centrifuged in a vacuum centrifuge for 30 min at 
37⁰C to dry the pellet completely. The pellets were then subjected to complete deglycosylation to 
remove any glycosaminoglycan chains or N- and O-linked oligosaccharides which might interfere with 
antibody binding. Deglycosylation was performed by adding to the pellet a deglycosylation buffer 
(150mM NaCl, 50mM sodium acetate pH6.8, 10mM EDTA and supplemented with protease 
inhibitors) with enzymes: heparinase (1:500), chondroitinase ABC (1:100), keratinase (1:500) (All 
Sigma-Aldrich), PNGaseF (1:200), and 3 different debranching enzymes: α2-3,6,8,9-Neuraminidase 
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(1:200), ß-N-acetylglucosaminidase (1:200) and O-glycosidase for complete removal of O-linked 
sugars (1:200) (all from Millipore). These were incubated with shaking for 48 hours at 37⁰C. Sample 
buffer containing β-mercaptoethanol was added to the deglycosylated samples to a concentration of 
0.5 μg/μl in preparation for Western blotting.  
 
Western Blotting 
 Deglycosylated lysates were heated to 85°C for 10 minutes. A chamber was prepared with a 
gradient SDS gel of 4-16% acrylamide concentration. 5 μg of 0.5 μg/μl samples were then loaded into 
each well of the gel. The proteins were separated at 175 mV. Transfer was achieved in wet conditions. 
The proteins were electrophoretically transferred onto nitrocellulose membranes using 350 mA at 
RT for  2 hours. Membranes were blocked for 1 hour with 5% Milk in PBS with tween (PBS-T). Primary 
antibodies were added with PBS-T/5% bovine serum albumin and incubated overnight at 4°C. The 
membrane was washed 3x15 min with PBS-T. The blots were then incubated in secondary antibody 
conjugated to HRP for 1 hour. The blots were again washed 3x15 min with PBS-T and bound antibody 
was detected by ECL detection (GE Healthcare) onto film. Images were scanned and imported to 
Image Studio Lite (Li-Cor Biosciences) for densitometric analysis. 
 
Immunofluorescence staining 
 Tissue was removed from storage at -80°C, warmed to -20°C for approximately 1 hour, then 
mounted onto the stage of a cryostat with OCT compound and allowed to equilibrate to the ambient 
temperature of the cryostat for 5 min. For cutting tissue, the stage temperature was set to -22°C and 
the knife was set to -20°C. The sections were then cut to 10 μm thick and mounted onto high quality 
superfrost slides. The sections were allowed to air dry for approximately 1 hour and then stored at -
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80°C. For staining, sections were allowed to dry completely and fixed by immersion, in a coplin jar, in 
pre-cooled 100% methanol at -20°C for 5 min or 4% formalin for 10 min RT. Sections were washed 
2x5 min in PBS, then permeabilized in 0.5% NP-40 for 3 min RT and washed 3x5 min in PBS. Sections 
were blocked for 1 hour at room temperature in 5% donkey serum. Primary antibody was diluted 
appropriately in blocking solution, applied to the sections and incubated in a humidified chamber 
overnight at 4°C. Sections were washed 3x5 min in PBS and secondary antibody conjugated to a 
fluorophore was diluted as appropriate, applied to the sections and incubated in the dark in a 
humidified chamber for 1 hour RT. DAPI was added 1:10,000 for 5 min at the end of the incubation 
for visualization of nucleic structures. Sections were washed 3x5 min in PBS in the dark and then 
mounted in mowiol mounting media and allowed to dry in the dark overnight. Images were acquired 
with an A1R point scanning confocal microscope (Nikon) 
 
Antibodies 
 The antibodies used in this investigation were: Anti-asporin (Thermo Fisher, PA5-13553) 
polyclonal rabbit IgG, diluted 1:1000 for WB and 1:100 for IF. Anti-collagen I (Abcam, ab90395), 
monoclonal mouse IgG1, clone COL-1 diluted 1:1000 for IF. Anti-lumican (Santa Cruz, sc-33785), 
polyclonal rabbit IgG, diluted 1:100 for WB. Anti-Mimecan/Osteoglycin (Abcam, ab110558) 
polyclonal rabbit IgG, diluted 1:1000 for WB. Anti-myomesin (gift from Elisabeth Ehler), mouse 
monoclonal IgG, clone B4 diluted 1:100 for IF. In the case of asporin, where band specificity was 
difficult to determine, we performed sequence alignment of the epitope and discovered homology 
to biglycan, which has predicted molecular weight ~5 kDa smaller than asporin; we therefore believe 
the lower band visible on the membrane identifies biglycan. The higher band, we ascribe to 
incomplete removal of glycosaminoglycans. 
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Statistical analysis 
Results of clinical investigations (CMR, cardiopulmonary exercise testing and 
echocardiography) were expressed as mean ± SD. Data from functional experiments, qPCR 
experiments and image analysis of picrosirius red staining were plotted individually and expressed as 
mean ± SD. Where appropriate, Student’s unpaired t-test was applied to test for differences between 
rToF-PVR and RV Donor groups. For the functional data (force, ktr, pCa50), the data from multiple 
myocytes were averaged for each patient and the mean value for each patient was taken as a single 
datum point for the subsequent calculation of overall mean, SD and the t-tests. Because of the 
technically challenging nature of the work, the number of myocytes per patient/donor was variable 
(ranging from 1-6). If distribution of the data were not normal, Mann-Whitney test was used, whilst 
Welch’s correction was applied when the variance was unequal between data sets. For transcriptome 
(mRNA) analysis, two-group comparison with t-test was performed and a threshold P value of 0.004 
and false discovery rate (q) of 0.47 were selected for principal component analysis and hierarchical 
clustering. For Gene Ontology enrichment, a hypergeometric test was used with P < 0.05 adjusted by 
Benjamini-Hochberg correction. 
 
Results 
Patients’ characteristics  
 Eight patients underwent pulmonary valve replacement, with a mean age of 24 ± 12 years (range 
11-49 years). Seven out of eight patients had a trans-annular patch at the time of initial ToF repair 
and two out of eight patients were previously palliated with a right modified BT shunt. One patient 
had initial ToF repair with valve preservation (age 3 months) and required subsequent balloon 
valvotomy (age 9 months) and re-do repair with trans-annular patch (age 10 months). Only two 
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patients had associated comorbidities; one patient (age 15 years at the time of PVR) suffered from 
mild right hemiplegia as result of an embolic event at the time of primary repair and had some 
hearing impairment, whereas another patient (age 11 years at the time of PVR) had a history of  high 
level of consanguinity and presented with IUGR (intra-uterine growth restriction), with associated 
learning difficulties, bilateral Perthes disease, and eczema. Only one patient (age 49 years) was on 
medication prior to PVR; medications included betablocker (bisoprolol 1.25mg), aspirin 75mg, and 
diuretics given only a few weeks before surgery (frusemide 20mg and spironolactone 25mg). 
Patients’ characteristics are summarized in Table 2. All patients had severe pulmonary valve 
regurgitation (PV RF 48 ± 7%), whereas there was no evidence of significant residual RVOT 
obstruction (mean RVOT peak velocity 2.2 ± 0.4 m/s). The right ventricle was significantly dilated, 
with an RV EDVi of 149 ± 26 ml/m2 and a RV:LV EDVi ratio of 2.2±0.4 but with preserved systolic 
function (RV EF 56 ± 5%). Left ventricular volumes and systolic function were normal in all (mean LV 
EDVi 71 ±19ml/m2, mean EF 66 ± 7%). Two patients had moderate tricuspid regurgitation (TR), 1 
patient mild TR, the others trivial or none. Upon cardiopulmonary exercise testing, exercise capacity 
was found to be only mildly reduced: mean peak VO2 measured 31 ± 8 ml/min/kg (84 ± 11% of 
predicted) with a VE/VCO2 slope of 28 ± 4.  
 Non-diseased RV tissue samples from 7 unused donor hearts were used as a reference in this 
study. The donors were selected so that their gender and age profiles (4 males, 3 females; patient 
age 28 ± 13 yr.) resembled those of the rToF-PVR patients. Five of the seven donors had suffered a 
subarachnoid hemorrhage after a motor vehicle accident, one donor died from a basal infarct after 
a grand mal seizure, and one donor died from hypoxia secondary to a seizure. Before explant the 
hearts were classed as “healthy” but were not used for transplantation owing to lack of a tissue type 
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match. LV or RV tissue from the same hearts has been used as reference tissue in previous 
publications by ours and other laboratories.15, 17-21 
 
Stiffness and contractile function were similar between permeabilized rToF-PVR and RV donor 
myocytes  
 Previous studies have found that in left or right heart failure there are changes in the passive 
stiffness and Ca2+-activated force development of the cardiac myofilaments (see Discussion); in vivo 
these alterations would be expected to contribute to diastolic and systolic dysfunction, respectively. 
We investigated whether similar changes could be observed with the myofilaments from the right 
ventricles of the rToF-PVR patients by measuring force development in permeabilized myocytes (Fig. 
1). The donor and rToF-PVR permeabilized myocytes used in the functional experiments had similar 
cross-sectional areas: 395 ± 66 µm2 vs 411 ± 57 µm2, for donor and rToF-PVR myocytes, respectively. 
For each myocyte, we first measured the passive stiffness of the myofilaments, as assessed by the 
increase in passive force upon sarcomere stretch from 2.0 µm to 2.3 µm. There was some variability 
between the passive stiffnesses of the permeabilized myocytes within and between patient samples, 
but overall there was no significant difference in passive stiffness between the rToF-PVR and donor 
myocytes (Fig. 1B), with passive forces of 5.36±1.82 kN.m-2 (n=6 patients) and 4.83±2.23 kN.m-2 (n=7 
donors; P = 0.65, unpaired t-test of patients vs donors), respectively.  
 Following the passive stiffness measurements, the myocytes were activated with Ca2+ and their 
Ca2+-activated contractile properties were studied, for the following key parameters: Maximum Ca2+ 
activated force (Fig. 1C) was 16.3±5.6 kN.m-2 in rToF-PVR patients (n=7 patients) and 14.1±4.1 kN.m-
2  in RV donors (n=7 donors; P = 0.42). Crossbridge cycling kinetics, ktr, at maximal Ca2+ (Fig. 1D) were 
2.01±0.39 s-1 (n=7 patients) and 2.08±0.23 s-1 (n=7 donors; P = 0.70). The Ca2+ sensitivity of force 
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development (Fig. 1E), as quantified by the pCa50 value (Fig. 1F), was 5.80±0.19 (n=7 patients) and 
5.80±0.20 (n=5 donors; P= 0.97). Thus none of these resting or Ca2+-activated contractile parameters 
showed a difference between rToF-PVR patients and donors. From these results, we conclude that 
the contractile function of myofibrils in permeabilized myocytes from the rToF-PVR patients was 
similar to that in donor myocytes.  
 
Collagen content was similar in rToF-PVR and RV Donor tissue. 
 Collagens I and III are the major ECM protein constituents in the heart and these, together with 
lysyl oxidase that cross-links the collagen, are known to be the main determinants of tissue stiffness.22 
Quantitative PCR for mRNA expression of genes coding for collagen I, collagen III and lysyl oxidase 
(COL1A2, COL3A1 and LOX, respectively) revealed that rToF-PVR tissue was comparable with RV 
donor (Fig. 2A-C). Direct assessment of tissue structure by picrosirius red showed no quantifiable 
difference between the collagen content of rToF-PVR and RV donor tissue under either brightfield or 
circular polarized light (Fig. 2D, 2E). The latter was used to visualize only the highly birefringent fibers 
and identify potential deleterious organization of collagen that occurs as the fibrotic scar matures. In 
this setting only the birefringent (bright) fibers are detected and indicate a predominance of collagen 
I over collagen III.23 
 
Transcriptomic profiling revealed up-regulation of small leucine-rich proteoglycans in rToF-PVR  
 An Affymetrix human microarray was used to profile gene expression differences between heart 
tissue of rToF-PVR patients and RV donors. Principal component analysis, a multivariate analysis 
which places individual samples in 3-dimensional space relative to each other based on false 
discovery rate (q) and P-value, was performed. Application of thresholds (q=0.47 and P=0.004) 
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showed clear clustering of samples within groups and clear separation between rToF-PVR and RV 
donor samples (Fig. 3A) and yielded a list of 601 transcripts, of which 330 encoded known genes 
(Supplemental Table). Hierarchical clustering showed grouping by disease, with consistent groups of 
up- and downregulated genes that were evenly distributed (Fig 3B). Volcano analysis showed that 
the differentially-regulated genes carrying the greatest degree of statistical significance were 
downregulated in rToF-PVR myocardium (Fig. 3C). Gene Ontology (GO) pathway analysis clusters the 
differentially regulated transcripts by utilizing databases of gene names (or ‘ontologies’) based on 
known associations as found in the existing body of literature. Using this method we determined that 
‘connective tissue diseases’, ‘response to wounding’, ‘inflammation’ and ‘immune response’ were 
top scoring terms i.e. ones with the lowest P value, within their categories (Diseases by biomarkers, 
GO Processes, Process networks and pathway maps respectively) (Fig. 4). Visualization of the top 
‘Pathway Map’ - immune response_Lectin induced complement pathway - showed that the 
transcripts in these pathways were predominantly downregulated (Fig. 5).  
 Lists of the 10 most up- and down-regulated transcripts according to fold change (Table 3) 
showed that genes encoding asporin, lumican and osteoglycin, which are all members of the family 
of SLRP extracellular matrix proteins, were upregulated in rToF-PVR heart tissue compared with RV 
donor. Gene set enrichment analysis showed that ‘ECM proteoglycans’ displayed a modest 
enrichment of genes at the leading edges of the analysis and transcripts were equally distributed 
between up- and down regulation (Fig. 6). 
 
SLRP gene expression is not corroborated by protein abundance in rToF-PVR myocardium 
To check the transcriptomics data relating to SLRP expression, we employed qPCR, which 
confirmed that genes for asporin (ASPN), lumican (LUM) and osteoglycin (OGN) all underwent 
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significant increases in mRNA expression in rToF-PVR myocardium (Fig. 7A). We then investigated 
their expression at the protein level. Western blotting showed a band corresponding to the predicted 
43 kDa molecular weight for asporin in rToF-PVR samples and showed a trend towards increased 
expression (P=0.07) compared with RV donor samples. Lumican expression was similar between the 
groups, whilst osteoglycin, which is expressed in pre- (~40 kDa) and post- (~20 kDa) processed 
forms,24 was expressed heterogeneously within and between groups (Fig. 7B). Overall, changes in 
protein abundance of these SLRPs was absent, with the exception perhaps of asporin which showed 
a tendency towards an increase in rToF-PVR samples compared with RV donors, though this will need 
examining further.  
Immunofluorescence co-staining for asporin and the myofilament protein marker, myomesin, 
showed that asporin was mainly localized to non-myocyte populations, but also appeared in the 
intercalated disc of the myocytes (Fig. 8). Subjectively, no obvious differences between cohorts were 
observed. 
Discussion 
This is the first investigation, to our knowledge, of myofilament function, tissue structure and mRNA 
expression in the RV myocardium of adult, or near-adult, rToF patients requiring pulmonary valve 
replacement. We found no differences in the passive stiffnesses or the active contractile properties 
of the myofilaments in rToF-PVR myocytes compared with those in RV myocytes from donor hearts. 
Whilst we discovered subtle molecular differences in the ECM that may indicate an early phase of 
tissue remodeling in the RV of rToF-PVR patients, overall the myocardium of rToF patients 
undergoing PVR replacement based on current clinical criteria appears not to have undergone 
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substantial remodeling at the cellular level, which should be beneficial for a successful post-operative 
recovery. 
 
Functional assessment of rToF-PVR cardiomyocytes 
 Previous studies have established that chronic dilation of the left ventricle, such as that triggered 
by MI or aortic regurgitation, leads to major changes to the contractile apparatus within the 
myocytes. For example, the passive stiffness of left ventricular myocytes is increased, due to changes 
in the expression and phosphorylation of the structural protein titin (which links actin and myosin 
filaments in the myofibril).10, 12 This would tend to increase the diastolic stiffness of the ventricle. The 
Ca2+-sensitivity of the myofibrils is increased due to a reduced phosphorylation of the regulatory 
protein troponin-I,10, 25 and this would tend to increase systolic contraction of the ventricle, while 
slowing diastolic relaxation. The right ventricle too can show disease-dependent alterations within 
the myocytes that can influence the contractile state. Permeabilized myocytes from patients with 
pulmonary arterial hypertension and RV heart failure exhibit increased passive stiffness and 
maximum Ca2+-activated force production compared with donor myocytes, and these changes could 
contribute to RV diastolic dysfunction in pulmonary arterial hypertension.26, 27 To our knowledge, 
there have been no similar studies on the functional properties of myocytes from the volume-
overloaded RV tissue of rToF patients, taken at the time of PVR surgery. We found no difference in 
passive stiffness of rToF-PVR permeabilized cardiac myocytes, compared with myocytes from non-
diseased RV tissue (Fig. 1). Similarly, the steady-state properties (maximum force production, Ca2+ 
sensitivity) and dynamic properties (ktr) of the myocytes during Ca2+ activation were the same as with 
the RV donor controls. Thus, we did not find any of the pathological changes in myofibrillar function 
that have been seen previously in volume-overloaded LV or in pressure-overloaded RV. This suggests 
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that the rToF-PVR myocytes we studied were structurally sound and that any structural remodeling 
of the myocytes had not occurred or had not reached a pathological state detectable by our 
experiments. In summary, these myocytes were essentially ‘normal’ and did not display a functional 
phenotype that has been associated with a severely diseased ventricle. Supporting this conclusion, 
although the RV was severely dilated in these patients, the RV ejection fraction was within the normal 
range. 
  
Subtle changes in the ECM of the remodeled myocardium in rToF-PVR patients 
 ECM remodeling in which collagen content is increased is a cardinal feature of HF, as studied in 
left ventricle.28 We observed that collagen content of myocardium was similar between rToF PVR and 
RV donor myocardium (Fig. 2), which contradicts previous studies which showed apparent fibrosis by 
cardiac MRI.29 This may reflect the differences in the selectivity of the two modes of imaging, since 
MRI techniques rely on contrast agents that are thought to target scarred, inflamed or remodeled 
areas, whereas picrosirius red staining very specifically detects collagen fibers. We discovered subtle 
changes in ECM gene expression in rToF-PVR tissue compared with donor RV tissue. Tissue 
microarray revealed that there were differences in gene expression between donor RV myocardium 
and rToF PVR myocardium in 601 transcripts when subjected to a p value threshold of p<0.04 and a 
q of 0.47. The selection of these thresholds was determined because samples became functionally 
grouped at this point. The gene list that was generated (Figure 4) revealed that ‘connective tissue 
diseases’ were well represented, implicating the ECM changes in diseased tissue. Moreover, 3 of the 
top 10 transcripts from genes known to encode proteins belonged to the family of small leucine-rich 
proteoglycans (SLRPs). GO analysis of our transcriptomics data showed that immune related 
processes were also strongly implicated and we hypothesized as to whether inflammation was 
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contributing to an ECM disease milieu. However, analysis of pathway maps confirmed that the 
overwhelming majority of the players in the immune pathways were downregulated (Figure 5), 
making this unlikely. A note of caution is required with regard to the interpretation of our gene 
ontology analysis since the q threshold of 0.47, is notably low and may have led to substantial false 
hits. However, this was unavoidable because stricter thresholds would have resulted in a very limited 
list of genes for GO analysis and our intention was to validate ‘hits’ which supported our hypothesis 
with further experimentation.  
 Proteoglycans are ECM-modifying proteins which regulate the manner in which the core 
components of the ECM, i.e. collagens, interact with each other and with the surface of cells .30 They 
are highly negatively-charged molecules that can facilitate hydration of the extracellular spaces to 
form gel-like structures such as the glycocalyx on the outer surface of cell membranes, potentially 
behaving as an ECM lubricant.31 The rheological properties of proteoglycans are important in 
determining the surface mechanical properties of tissue and there is a growing realization that 
dysregulation of proteoglycans may contribute to pathological remodeling of the myocardium . For 
example, decorin and biglycan become highly expressed in models of hypertrophy and heart failure, 
and are responsible for facilitating fibrillogenesis and fibrosis.32 
 We identified increased mRNA for the SLRPs asporin, lumican and osteoglycin in rToF-PVR 
myocardium. Of these three, only asporin displayed a tendency for increased abundance at the 
protein level in rToF-PVR samples. However, the functional significance of this is unclear at present, 
because little is understood about the role of asporin in the heart. Upregulation of asporin has been 
observed during ECM remodeling in a pig model of myocardial infarction,33 but further work is 
required to establish the importance of asporin in right ventricle function. In conclusion, our study 
provides evidence that the myocardium of rToF PVR patients undergoing pulmonary valve 
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replacement shows very little disturbance to myofilament function, histological structure and protein 
abundance, whilst gene expression changes may be indicative of an early response to volume 
overloading in these patients but this requires further investigation.  
 
Clinical perspectives 
Current indications of PVR are based on results of non-invasive assessment, including 
volumetric and cardiac systolic function assessment with CMR imaging, clinical evaluation of 
symptoms and objective assessment of exercise capacity using cardiopulmonary exercising testing 
modality. However, it is difficult to predict which patients will most improve after PVR. In a previous 
study we found that younger patients (<17.5 years) undergoing PVR exhibited greater 1-year 
improvement of LV dynamics and exercise capacity than in older patients. We suggested that the 
better outcome post-PVR in the younger patients could be due to a more compliant, less “diseased” 
right ventricle, perhaps reflecting better myocardial protection at the time of primary repair and a 
shorter exposure to volume overload.7 However, the present results, which were performed mostly 
on patients in the older age range, did not show evidence for substantial myocardial disease, at least 
at the cellular and ECM levels. Thus, in these patients, approximately 20 years after ToF repair and 
with severe pulmonary regurgitation, the contractile properties of the RV myofibrils and the ECM 
composition and structure were comparable to those in normal RV tissue. This suggests that the 
poorer outcome that we observed previously in the older patient group is unlikely to be due to a 
poorer reversibility of myocyte and ECM function. Thus, current clinically-based predictive indices 
used to inform timing of PVR may be fit for purpose and are unlikely to subject patients to the risk of 
irreversible adverse remodeling of the RV. 
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We did find subtle changes in the expression of ECM genes in the rToF-PVR patients. Whether 
these changes might signal the impending onset of detrimental changes in collagen structure and 
myofibril function remains a topic for future studies.  
 
Limitations 
 One of the main study limitations is the small number of available patients and the small amount 
of tissue that could be obtained from each, which did not allow us to test for any correlation between 
myocyte/ECM properties and age at the time of PVR. A more extensive study will be needed to 
address this potential correlation. Another potential limitation comes from the source of the tissue 
samples in the RV. Of necessity, we could obtain tissue only from the RV infundibulum when 
removing excessive residual muscle bundles. Whilst there is the potential that these samples might 
not be representative of the whole RV myocardium, these tissue sites have been exposed to the same 
chronic volume overload as the other areas within the RV, so the properties of their myocytes and 
ECM might be expected to be representative of those throughout the whole RV. Finally, the rToF-
PVR samples and the donor samples came from patients having different clinical histories and from 
two different countries (patients undergoing PVR in the UK; brain-dead patients maintained on life 
support in Australia). However, using the same donor samples as a reference tissue, many studies 
have discovered substantial changes in myofilament function in other types of RV or LV disease,21 so 
we have confidence that our finding of no change in myofilament function between the donor and 
rToF-PVR samples is a valid result. 
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Figures 
 
Figure 1. Passive stiffness and Ca2+ activated force in “permeabilized” cardiac myocytes from 
patients with Tetralogy of Fallot repair undergoing pulmonary valve replacement (rToF-PVR) are 
similar to those from right ventricle (RV) donors. A, A typical force trace showing activation of a 
single myocyte by an increase in solution Ca2+ and the measurement of Ca2+-activated force and 
crossbridge kinetics (ktr). For panels B-D & F each small symbol shows the result from one myocyte 
and each large symbol shows the mean derived from replicate myocytes from each donor or patient. 
The horizontal bars show the overall mean ± SD, calculated using each mean value derived from 
replicate myocytes (large symbols) as a single datum for the statistical analysis. B, Passive force, 
measured as the difference between passive forces at sarcomere lengths 2.0 µm and 2.3 µm. 19 RV 
donor myocytes (1-6 myocytes from each of 7 donors used in this panel), 16 rToF-PVR myocytes (1-
4 myocytes from each of 6 rToF-PVR patients used in this panel). C, Maximum Ca2+-activated force, 
corrected for myocyte cross-sectional area. 23 donor myocytes (1-6 myocytes from each of 7 donors), 
19 rToF-PVR myocytes (1-4 myocytes from each of 7 patients). D, Rate of redevelopment of force (ktr) 
after a release/restretch protocol at maximum Ca2+. 21 donor myocytes (1-6 myocytes from each of 
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7 donors), 19 rToF-PVR myocytes (1-4 myocytes from each of 7 patients). E, Force-Ca2+ relationship. 
All forces are expressed relative to the maximum force at 30 µmol/L Ca2+. In this panel the symbols 
show overall means ± SD for each [Ca2+]. 1-6 myocytes from each of 5 donors, 1-4 myocytes from 
each of 7 patients. F, Ca2+ sensitivity, expressed as the pCa50 value: -log of [Ca2+] required for 50% 
activation of force, and serves as a summary variable for the same data as in panel E. Statistical 
analysis showed no significant differences (P>0.05, unpaired t-tests) between the overall mean data 
for RV Donor and rToF-PVR patients for any of the measured parameters.  
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Figure 2. The collagen matrix in myocardium of patients with Tetralogy of Fallot repair undergoing 
pulmonary valve replacement (rToF-PVR) is similar to that in right ventricle (RV) donor myocardium. 
A, quantitative PCR analysis of mRNA expression for collagen I (COL1A2), collagen III (COL3A1) and 
lysyl oxidase (LOX) indicated no differences between rToF-PVR and RV donor myocardium. Each data 
point shows the result from one donor or rToF-PVR patient. B, Picrosirius red staining of collagen 
fibers in RV donor and rToF-PVR heart tissue sections with quantitation of the dark-red stained 
collagen fibers as a percentage of total tissue area. C, The same sections were viewed under polarized 
light to assess the presence of irreversibly linked collagen as a percentage of total tissue area. No 
statistical differences were observed between groups for all assays described. RV donor n=7, rToF PVR 
n=5. Values are expressed as mean ± SD. Scale = 30 μm.  
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Figure 3. Analysis of the transcriptome identifies gene expression changes in myocardium of 
patients with Tetralogy of Fallot repair undergoing pulmonary valve replacement (rToF-PVR). A, 
Principal Component analysis of the gene expression profile of each tissue sample in relation to all 
others in the first 3 principal components revealed clear functional grouping of samples according to 
right ventricle (RV) donor (black) and rToF-PVR (magenta). Each data point shows the result from one 
RV donor or rToF-PVR patient. B, Hierarchical clustering also showed rToF-PVR samples were 
functionally grouped according to gene expression profile. Selected thresholds were a false discovery 
rate (q) of 0.47 and P=0.004. C, Volcano analysis revealed that the most profound differences occurred 
in downregulated genes. The transcripts ASPN, LUM and OGN were upregulated in rToF-PVR samples. 
Statistical measures applied to the dataset prior to analysis were a p value of 0.004 and a false 
discovery rate of 0.47. RV donor n=6, rToF-PVR n=7.  
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Figure 4. Gene ontology analysis implicated tissue remodeling and inflammation pathways as 
dysregulated in myocardium of patients with Tetralogy of Fallot repair undergoing pulmonary valve 
replacement (rToF-PVR). Holistic analysis of the differentially expressed genes in rToF-PVR 
myocardium compared with right ventricle donor against the gene ontology (GO) annotated database 
of affected biological processes ordered according to P value.  
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Figure 5. Schematic representation of the top scoring statistically significant pathway map 
indicated down regulation of genes involved in immune response in myocardium of patients with 
Tetralogy of Fallot repair undergoing pulmonary valve replacement. The top scoring map (map 
with the lowest p-value) based on enrichment distribution sorted by 'statistically significant maps' 
was Immune response_Lectin induced complement pathway. This shows negative regulation (blue 
thermomemeter) of most of the genes involved in this pathway implying suppression of immune 
pathways in rToF-PVR myocardium. Only one gene displayed upregulated expression (red 
thermometer). Many of the genes in the second and third top scoring maps overlapped with this 
map. The material in this figure is reproduced under a licence from Clarivate Analytics. You may not 
copy or redistribute this material in whole or in part without the written consent of Clarivate 
Analytics. 
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Figure 6. Gene set enrichment analysis showing the expression patterns of the Extracellular 
Matrix proteoglycan gene set in patients with Tetralogy of Fallot repair undergoing pulmonary 
valve replacement (rToF-PVR) compared with right ventricle (RV) donor myocardium. A, Gene Set 
Enrichment Analysis of extracellular matrix proteoglycans displaying some enrichment of genes at 
the leading edge. B, Corresponding heat map of genes and expression profiles for 6 RV donor 
samples and 7 rToF-PVR samples. 
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Figure. 7. Validation of small leucine rich proteoglycan (SLRP) gene and protein expression shows 
asporin to be upregulated in several myocardial samples from patients with Tetralogy of Fallot 
repair undergoing pulmonary valve replacement (rToF-PVR). A, mRNA validation of gene expression 
was performed by qPCR analysis for the genes encoding asporin (ASPN), lumican (LUM) & osteoglycin 
(OGN). n=7/group. Each data point shows the result from one right ventricle (RV) donor or rToF-PVR 
patient. Values expressed as mean ± SD, indicated p values were returned after performing Mann-
Whitney U test. The p values were unchanged if the single rToF-PVR outlier was removed and the 
data analyzed using Student’s unpaired t-test. B, Protein expression analysis for these genes was 
performed by Western blotting using antibodies probing for asporin, lumican, osteoglycin. Ponceau 
S shows equal loading of the gel lanes. Densitometry was performed for quantitation of protein 
abundance relative to ponceau S. n=7 RV Donor, 5 rToF-PVR. Values expressed as mean ± SD; P values 
were returned following Mann-Whitney U tests. 
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Figure 8. Immunostaining of sections for asporin shows localization in extracellular domains and 
the intercalated disc in human right ventricle. Asporin expression in right ventricle myocardium of 
both cohorts appeared in the extracellular domains in between the lateral membranes of 
cardiomyocytes suggestive of extraxcellular matrix localization (red arrows) or as regularly spaced 
bands indicative of intercalated disc staining (white arrows). Antibody to the sarcomere protein, 
myomesin, was used as a cardiomyocyte marker and DAPI was used to stain nuclear DNA. Scale bar 
= 10 μm. 
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Tables 
Table 1. Primers used in this investigation used for qPCR 
 
Gene Forward Reverse 
ASPN 5' - CTC TGC CAA ACC CTT CTT TAG C - 3' 5' - CGT GAA TAG CAC TGA CAT CCA A - 3' 
LUM 5' - TAA CTG CCC TGA AAG CTA CCC - 3' 5' - GGA GGC ACC ATT GGT ACA CTT - 3' 
OGN 5' - TCT ACA CTT CTC CTG TTA CTG CT - 3' 5' - GAG GTA ATG GTG TTA TTG CCT CA - 3' 
COL1A2 5' - GAG CGG TAA CAA GGG TGA GC - 3' 5' - CAC CCT GTG GTC CAA CAA CTC - 3' 
COL3A1 5' - GGA GCT GGC TAC TTC TCG C - 3' 5' - GGG AAC ATC CTC CTT CAA CAG - 3' 
LOX 5' - GCC GAC CAA GAT ATT CCT GGG - 3' 5' - GCA GGT CAT AGT GGC TAA ACT C - 3' 
GAPDH 5' - GGA GCG AGA TCC CTC CAA AAT - 3' 5' - GGC TGT TGT CAT ACT TCT CAT GG - 3' 
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Table 2. Patients’ characteristics: demographic, transthoracic echocardiogram (TTE), 
cardiopulmonary exercise testing (CPET) and cardiac MR imaging (CMR) data  
 Patients (n=8) 
Male:Female ratio 3:5 
Age at repair (years) 2±2.6 
Age at PVR (years) 24±12 
NYHA  I (2), II (6) 
TTE  
TAPSE (mm) 21±4 
TR velocity (m/s) 2.5±0.4 
RVOT peak velocity (m/s) 2.2±0.4 
CPET  
Peak VO2 (ml/min/kg) 31±8 
Peak VO2 % of predicted 84±11 
VE/VCO2 slope 28±4 
Peak HR (bpm) 180±13 
CMR  
RV EDVi (ml/m2) 149±26 
 RV ESVi (ml/m2)  65±17 
 RV:LV EDV ratio   2.2±0.4:1 
 RV CO (L/m 2)  6.3±1.8 
RV EF (%) 56±6 
LV EDVi (ml/m2) 71±19 
LV EF (%) 66±7 
LV CO (L/m 2) 3.5±0.4 
PV RF (%) 48±7 
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PVR = pulmonary valve replacement; TAPSE=tricuspid annular systolic excursion; RV=right ventricle; 
LV=left ventricle; EDVi = end-diastolic volume indexed for body surface area; EF=ejection fraction; CO 
=cardiac output; PV RF=pulmonary valve regurgitant fraction 
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Table 3. The ten most up-regulated transcripts and ten most-downregulated protein coding 
transcripts  
Gene Title 
Gene 
Symbol 
Difference 
Fold 
change 
    
Up-regulated transcripts    
asporin ASPN 2.222 4.666 
guanylate cyclase activator 1C GUCA1C 1.799 3.481 
frizzled-related protein FRZB 1.383 2.608 
lumican LUM 1.108 2.156 
natriuretic peptide receptor C/guanylate cyclase C 
(atrionatriuretic peptide receptor C) 
NPR3 1.027 2.038 
osteoglycin OGN 0.9933 1.990 
crystallin, mu CRYM 0.9442 1.924 
Fc fragment of IgE, high affinity I, receptor for; alpha 
polypeptide 
FCER1A 0.899 1.865 
fibronectin type III domain containing 1 FNDC1 0.881 1.842 
endothelin receptor type A EDNRA 0.845 1.797 
    
Down-regulated transcripts    
RAS, dexamethasone-induced 1 RASD1 -1.672 0.313 
V-set and immunoglobulin domain containing 4 VSIG4 -1.738 0.299 
FK506 binding protein 5 FKBP5 -1.770 0.293 
S100 calcium binding protein A9 S100A9 -1.800 0.287 
coagulation factor XIII, A1 polypeptide F13A1 -1.811 0.284 
lymphatic vessel endothelial hyaluronan receptor 1 LYVE1 -1.929 0.262 
phospholipase A2, group IIA (platelets, synovial fluid) PLA2G2A -2.035 0.243 
serpin peptidase inhibitor, clade A (alpha-1 antiproteinase, 
antitrypsin), member 3 
SERPINA3 -2.183 0.220 
CD163 molecule CD163 -2.373 0.192 
metallothionein 1A MT1A -2.882 0.135 
 
 
